miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

Y Ji, C Wrzesinski, Z Yu, J Hu… - Proceedings of the …, 2015 - National Acad Sciences
Y Ji, C Wrzesinski, Z Yu, J Hu, S Gautam, NV Hawk, WG Telford, DC Palmer, Z Franco…
Proceedings of the National Academy of Sciences, 2015National Acad Sciences
Lymphodepleting regimens are used before adoptive immunotherapy to augment the
antitumor efficacy of transferred T cells by removing endogenous homeostatic “cytokine
sinks.” These conditioning modalities, however, are often associated with severe toxicities.
We found that microRNA-155 (miR-155) enabled tumor-specific CD8+ T cells to mediate
profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-
ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc …
Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic “cytokine sinks.” These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8+ T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.
National Acad Sciences